Takeda Pharmaceutical (TAK) said Tuesday the European Commission approved Adcetris in combination with a chemotherapy regimen to treat patients with stage 2b, 3 and 4 Hodgkin lymphoma.
The Commission's approval follows a recommendation from the Committee for Medicinal Products for Human Use on April 25, according to a statement.
The approval is based on the phase 3 HD21 trial, which achieved its co-primary safety and efficacy endpoints, the company said.
It added that the development marks the second approval for the drug regimen for the treatment of Hodgkin lymphoma.
Price: 14.99, Change: -0.09, Percent Change: -0.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。